Literature DB >> 18252264

HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review.

Amer Karam1, Jonathan S Berek, Amy Stenson, Jianyu Rao, Oliver Dorigo.   

Abstract

BACKGROUND: The treatment of Paget's disease of the vulva particularly for recurrences can be challenging. Overexpression of the HER-2/neu protein has been found in about 30% of vulvar Paget's cases therefore presenting a potential therapeutic target. CASE: We report the case of a 52-year-old patient with persistent Paget's disease of the vulva despite eight surgical excisions over a 15-year period. Immunohistochemistry demonstrated overexpression of the HER-2/neu protein in the vulva resection specimen. Treatment with Trastuzumab resulted in a significant regression of her disease and resolution of symptoms.
CONCLUSION: Based on our case report, therapeutic targeting of HER-2/neu for patients with Paget's disease of the vulva using for example Trastuzumab is a potentially effective, alternative approach, and warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18252264     DOI: 10.1016/j.ygyno.2007.12.014

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

Review 1.  Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.

Authors:  Henry D Reyes; Kristina W Thiel; Matthew J Carlson; Xiangbing Meng; Shujie Yang; Jean-Marie Stephan; Kimberly K Leslie
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

Review 2.  [Extramammary Paget's disease].

Authors:  I Cosgarea; A Zaremba; U Hillen
Journal:  Hautarzt       Date:  2019-09       Impact factor: 0.751

3.  Management of penoscrotal extramammary Paget disease: case series and review of the literature.

Authors:  P Moretto; V J Nair; S El Hallani; S Malone; E Belanger; C Morash; C M Canil
Journal:  Curr Oncol       Date:  2013-08       Impact factor: 3.677

4.  Determination of Tumor Heterogeneity in Colorectal Cancers Using Heterogeneity Tissue Microarrays.

Authors:  Phillip R Stahl; Jessica Schnellert; Christina Koop; Ronald Simon; Andreas Marx; Jakob R Izbicki; Guido Sauter; Alexander Quaas
Journal:  Pathol Oncol Res       Date:  2015-05-31       Impact factor: 3.201

5.  Concordance of the HER2 protein and gene status between primary and corresponding lymph node metastatic sites of extramammary Paget disease.

Authors:  Ryota Tanaka; Yuko Sasajima; Hitoshi Tsuda; Kenjiro Namikawa; Akira Takahashi; Arata Tsutsumida; Yasuhiro Fujisawa; Manabu Fujimoto; Naoya Yamazaki
Journal:  Clin Exp Metastasis       Date:  2016-06-11       Impact factor: 5.150

6.  Paget's Disease of the Vulva in Premenopausal Woman Treated with Only Surgery: A Case Report.

Authors:  Hamid Asmouki; Rachid Oumouloud; Abderrahim Aboulfalah; Abderraouf Soummani; Abdelouahed Marrat
Journal:  Case Rep Oncol Med       Date:  2012-09-16

7.  Successful and long-term response to trastuzumab plus paclitaxel combination therapy in human epidermal growth factor receptor 2-positive extramammary Paget's disease: A case report and review of the literature.

Authors:  Takashi Ichiyama; Daisuke Gomi; Toshirou Fukushima; Takashi Kobayashi; Nodoka Sekiguchi; Akiyuki Sakamoto; Shigeru Sasaki; Keiko Mamiya; Tomonobu Koizumi; Yoshihisa Hama
Journal:  Mol Clin Oncol       Date:  2017-09-19

Review 8.  Metastatic Extramammary Paget's Disease: Pathogenesis and Novel Therapeutic Approach.

Authors:  Keitaro Fukuda; Takeru Funakoshi
Journal:  Front Oncol       Date:  2018-02-16       Impact factor: 6.244

9.  Human epidermal growth factor receptor 2 amplification as a biomarker for treatment in patients with lymph node-metastatic penoscrotal extramammary Paget's disease.

Authors:  Xiaolin Lu; Peipei Zhang; Yao Zhu; Dingwei Ye
Journal:  Oncol Lett       Date:  2019-01-14       Impact factor: 2.967

10.  Extramammary Paget's Disease in Two Brothers.

Authors:  Xiaoting Zhang; Wanwan Jin; Haibo Zhu; Haifeng Yu
Journal:  Indian J Dermatol       Date:  2015 Jul-Aug       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.